EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Open Access

Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine

Robert L Atmar iD, Kirsten E Lyke iD, Christine M Posavad iD, Meagan E Deming iD, Rebecca C Brady iD, David Dobrzynski iD, Srilatha Edupuganti, Mark J Mulligan, Richard E Rupp iD, Christina A Rostad iD, Lisa A Jackson iD, Judith M Martin iD und 25 weitere

The Journal of Infectious Diseases · 15.10.2025 · 232 (4) · 971-981

DOI: 10.1093/infdis/jiaf176 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 29.04.2025. Verfasst von Robert L Atmar und 36 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Medicine and Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA. Hauptthemen laut MEDLINE: Antibodies, Viral, SARS-CoV-2, COVID-19, Immunization, Secondary. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NIAID NIH HHS, National Institutes of Health Vaccine Research Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mucosal immunity plays a critical role in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and replication. Understanding the capacity of coronavirus disease 2019 (COVID-19) vaccines to elicit both mucosal and systemic antibodies could help optimize vaccination strategies.

Methods

We conducted an open-label, phase 1/2 adaptive-design clinical trial to evaluate the safety and immunogenicity of COVID-19 immunizations. Healthy adults received 2 priming doses of mRNA-1273, a booster dose of mRNA-1273, and a second booster of bivalent (WA-1 and BA.4/BA.5) mRNA-1273.222. Adverse event data were collected. Serum and mucosal immunity were evaluated.

Results

One hundred six persons were enrolled. Thirty received all 4 study-related vaccine doses. All vaccines were well tolerated, with injection site pain, malaise, myalgias, and headache being the most frequently reported symptoms. Among those who received a second booster, 24 of 30 (80%) had serological evidence of SARS-CoV-2 infection. Following the second booster, increases in geometric mean binding and pseudovirus neutralization antibody titers to the ancestral strain and BA.1 and BA.5 variants were observed. Increases in mucosal immunoglobulin G and immunoglobulin A (IgA) antibodies in nasal and salivary samples were observed in both previously infected and infection-naive participants, although prior infection markedly boosted virus-specific mucosal IgA responses.

Conclusions

The mRNA-1273.222 booster vaccine was safe and immunogenic and induced mucosal antibody responses in previously infected and infection-naive persons. Clinical Trials Registration NCT04889209.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, ViralSARS-CoV-2COVID-19Immunization, SecondaryCOVID-19 VaccinesImmunity, MucosalHumansMaleFemaleAdultMiddle Aged2019-nCoV Vaccine mRNA-1273Young AdultAntibodies, NeutralizingAdolescentImmunoglobulin GImmunoglobulin AAntibody Formation

Stichwörter der Autor:innen

COVID-19SARS-CoV-2boosterimmunogenicityvaccine

Substanzen

Antibodies, ViralCOVID-19 Vaccines2019-nCoV Vaccine mRNA-1273Antibodies, NeutralizingImmunoglobulin GImmunoglobulin A

Autor:innen und Institutionen

  • Departments of Medicine and Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.
  • Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
  • Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Cincinnati Children's Hospital Medical Center, Division of Infectious Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • Division of Infectious Diseases, Department of Medicine, University of Rochester, Rochester, New York, USA.

ORCID-Profile: Robert L Atmar, Kirsten E Lyke, Christine M Posavad, Meagan E Deming, Rebecca C Brady, David Dobrzynski, Richard E Rupp, Christina A Rostad, Lisa A Jackson, Judith M Martin, Mallory C Shriver, Angelica C Kottkamp, Angela R Branche, Robert W Frenck, Christine Johnston, Tara M Babu, Martín Bäcker, Daniel Szydlo, Elizabeth R Brown, David C Montefiori, Amanda Eaton, Kathleen M Neuzil, John H Beigel, Marcela Pasetti, Paul C Roberts

Förderung

  • NIH HHS
  • NIAID NIH HHS
  • National Institutes of Health Vaccine Research Center
  • Infectious Diseases Clinical Research Consortium
  • National Institute of Allergy and Infectious Diseases
  • NIAID Collaborative Influenza Vaccine Innovation Centers
  • Vaccine Research Center
  • National Institutes of Health

Zitieren

APA

Atmar, R. L., Lyke, K. E., Posavad, C. M., Deming, M. E., Brady, R. C., Dobrzynski, D., Edupuganti, S., Mulligan, M. J., Rupp, R. E., Rostad, C. A., Jackson, L. A., Martin, J. M., Shriver, M. C., Rajakumar, K., Coler, R. N., El Sahly, H. M., Kottkamp, A. C., Branche, A. R., Frenck, R. W., …, & Roberts, P. C. (2025). Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine. The Journal of Infectious Diseases, 232(4), 971-981. https://doi.org/10.1093/infdis/jiaf176

Vancouver

Atmar RL, Lyke KE, Posavad CM, Deming ME, Brady RC, Dobrzynski D, et al. Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine. The Journal of Infectious Diseases. 2025;232(4):971-981. doi:10.1093/infdis/jiaf176

BibTeX
@article{Atmar2025,
  author = {Atmar, Robert L and Lyke, Kirsten E and Posavad, Christine M and Deming, Meagan E and Brady, Rebecca C and Dobrzynski, David and Edupuganti, Srilatha and Mulligan, Mark J and Rupp, Richard E and Rostad, Christina A and Jackson, Lisa A and Martin, Judith M and Shriver, Mallory C and Rajakumar, Kumaravel and Coler, Rhea N and El Sahly, Hana M and Kottkamp, Angelica C and Branche, Angela R and Frenck, Robert W and Johnston, Christine and Babu, Tara M and Bäcker, Martín and Archer, Janet I and Crandon, Sonja and Nakamura, Aya and Nayak, Seema U and Szydlo, Daniel and Dominguez Islas, Clara P and Brown, Elizabeth R and O'Connell, Sarah E and Montefiori, David C and Eaton, Amanda and Neuzil, Kathleen M and Stephens, David S and Beigel, John H and Pasetti, Marcela and Roberts, Paul C},
  title = {Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  volume = {232},
  number = {4},
  pages = {971--981},
  doi = {10.1093/infdis/jiaf176}
}
Kostenlos starten →